CG in the News
2023
ENDPOINTS NEWS
May 24, 2023
Endpoints 20 under 40 – Arthur Kuan is featured
ONCOLOGY TUBE
May 23, 2023
Pembrolizumab combined with CG0070. How can this help patients with NMIBC? Roger Li
MEDPAGE TODAY
May 03, 2023
‘Fantastic,’ ‘Terrific’ Results With Oncolytic Virus Combo for Bladder Cancer
ONCLIVE
April 29, 2023
Phase 2 Data Show Clinical Activity With CG0070 Plus Pembrolizumab in NMIBC
MEDPAGETODAY
March 01, 2023
Emerging Therapies in Non-Muscle-Invasive Bladder Cancer
EVALUATE
Februry 02, 2023
A renewed push into early bladder cancer
2022
BIOCENTURY
November 18, 2022
Oncolytic virus combinations move beyond checkpoint inhibitors
UROLOGY TIMES
November 15, 2022
Combo of oncolytic immunotherapy and pembrolizumab continues to show promise in BCG-unresponsive NMIBC
ENDPOINTS NEWS
November 15, 2022
Can an oncolytic virus therapy challenge the standard of care in bladder cancer? CG Oncology has $120M to find out
WALL STREET JOURNAL
November 15, 2022
Venture Capitalists Back CG Oncology’s Search for New Bladder Cancer Treatment
ENDPOINTS NEWS
November 10, 2022
CG Oncology spotlights oncolytic virus combo data ahead of full readout due next year
CANCER NETWORK
June 23, 2022
Roger Li, MD, Provides In-Depth Description of CG0070 Mechanism of Action in Bladder Cancer
BIOSPACE
June 6, 2022
CG Oncology Teams with Merck, BMS for Positive Bladder Cancer Results
ENDPOINTS NEWS
June 6, 2022
#ASCO2022 roundup: CG Oncology builds on head-turning combo data; EQRx doesn’t have a way into US markets
CANCER NETWORK
April 13, 2022
Oncolytic Adenovirus, CG0070, Plus Pembrolizumab Shows Promise in BCG-Unresponsive NMIBC
INSIDER
Sep 13, 2022
Arthur Kuan Featured in 30 Leaders under 40 Changing Healthcare in 2022
BIOSPACE
April 5, 2022
CG Oncology’s Bladder Cancer Therapy Impresses at AACR
TARGETED ONCOLOGY
April 24, 2022
CG0070 With Pembrolizumab Shows Encouraging Results in BCG-Unresponsive NMIBC
TARGETED ONCOLOGY
June 21, 2022
CG0070 Provides Durable Responses in Certain Patients with Non-Muscle Invasive Bladder Cancer
ARGETED ONCOLOGY
May 16, 2022
Results of CG0070 Combined With Pembrolizumab in BCG-Unresponsive NMIBC
2021
MEDCITY NEWS
August 23, 2021
CG Oncology CEO highlights biotech’s oncolytic immunotherapy for bladder cancer
CGT LIVE
August 4, 2021
Advantages of CG0070 Over Standard Care for Non-Muscle Invasive Bladder Cancer
CGT LIVE
July 30, 2021
CG0070: A Genetically Modified Immunotherapy for Non-Muscle Invasive Bladder Cancer
CANCER NETWORK
Nov 23, 2021
CG0070 Plus Pembrolizumab Yields Positive Preliminary Data in Non-Muscle Invasive Bladder Cancer
CLINICAL TRIALS ARENA
Nov 15, 2021
CG Oncology reports Phase II preliminary data on bladder cancer therapy
2020
WSJ
Dec 10, 2020
Drugmaker CG Oncology Grabs $47 Million for Bladder Cancer Trials
BIOCOM CATALYST AWARD
FIERCE BIOTECH
Dec 11, 2020
Oncolytic immunotherapy biotech CG Oncology nabs $47M round for late-stage cancer push
